Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH2 | Q6NS38 | 2/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.46 |
| ▸ | ALKBH1 | Q13686 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21901788 | 0.89 | LRRK2 (0.37) | ALKBH2HPGDSEGLN1ALKBH1 | |
| SCHEMBL20444063 | 0.83 | ALKBH1 (0.45) | ALKBH2HPGDSEGLN1ALKBH1 | |
| SCHEMBL20176158 | 0.83 | EGLN1 (0.47) | ALKBH2HPGDSEGLN1ALKBH1 | |
| SCHEMBL14692557 | 0.81 | EGLN1 (0.53) | ALKBH2HPGDSEGLN1ALKBH1 | |
| SCHEMBL18330392 | 0.80 | KCNH2 (0.35) | — | |
| SCHEMBL25342571 | 0.78 | EGLN1 (0.53) | ALKBH2HPGDSEGLN1ALKBH1 | |
| SCHEMBL16983155 | 0.76 | NOTUM (0.39) | — | |
| SCHEMBL16982972 | 0.76 | NOTUM (0.60) | — | |
| SCHEMBL16983112 | 0.76 | PTGS2 (0.34) | — | |
| SCHEMBL31583502 | 0.75 | EGLN1 (0.50) | ALKBH2HPGDSEGLN1ALKBH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3868753-B1 | FACTOR XIA MACROCYCLIC INHIBITORS BEARING A NON-AROMATIC P2' GROUP | BRISTOL MYERS SQUIBB CO (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3328851-B1 | FACTOR XIA MACROCYCLIC INHIBITORS BEARING ALKYL OR CYCLOALKYL P2' MOIETIES | BRISTOL MYERS SQUIBB CO (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-3310777-B1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20180186795-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-07-05 | — | — | US | disclosed |
| WO-2017019821-A1 | FACTOR XIA NEW MACROCYCLE BEARING A NON-AROMATIC P2' GROUP | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017019819-A1 | FACTOR XIA MACROCYCLIC INHIBITORS BEARING ALKYL OR CYCLOALKYL P2' MOIETIES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2016205482-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186795-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | ALKBH2 4793/4885HPGDS 455/4885EGLN1 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.